Intermittent Claudication
Findings in intermittent claudication reported from Y. Soga and co-researchers
Published in Blood Weekly, February 19th, 2009
According to a study from Kitakyushu, Japan, "Objectives The purpose of this study was to investigate whether cilostazol reduces restenosis and revascularization after endovascular therapy (EVT) for femoropopliteal lesions. Cilostazol improves walking distance in patients with intermittent claudication and reduces restenosis after coronary intervention, but its efficacy remains unclear after EVT for femoropopliteal disease."
" This study was performed as a multicenter, randomized, open-label clinical trial. Eighty patients (mean age 70.7 +/- 6.2 years, 84% men) with intermittent claudication due to a femoropopliteal lesion were randomly assigned to receive or not...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2009-02-19)
More Articles from Blood Weekly
- NIH/National Human Genome Research Institute
New findings raise questions about process used to identify experimental drug - Abscess
Researchers from University of Louisville describe findings in abscess - Coagulation
Cosmetic Surgery - No Killer Blood Clots to the Lungs Sans GA, PK Anesthesia Can Save the Day - Enzyme Research
Studies in the area of enzyme research reported from University of North Carolina - Fibrinolysis
Studies from H.Y. He et al have provided new data on fibrinolysis - Gene Therapy
Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
